

Sun Pharmaceutical Industries Ltd.,
SUN HOUSE, CTS No. 201 B/1,
Western Express HI Highway, Goregaon(E),
Mumbai 400063, India
Tel.: (91-22) 4324 4324 Fax.: (91-22) 4324 4343
CIN: L24230GJ1993PLC019050
www.sunpharma.com



23 April 2023

National Stock Exchange of India Ltd,
Exchange Plaza, 5th Floor,
Plot No. C/1, G Block,
Bandra Kurla Complex,
Bandra (East),
Mumbai – 400 051.

BSE Limited,
Market Operations Dept.
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai - 400 001.

Dear Sirs,

Sub: Update on Mohali facility

This is with respect to our prior communications, dated November 8, 2022 and August 13, 2022, regarding the US FDA inspection at the Company's Mohali (Punjab) facility from August 3 to August 12, 2022. As stated earlier, US FDA had classified the inspection as "Official Action Indicated" (OAI).

We now wish to inform you that the Company has received a letter titled "CONSENT DECREE CORRESPONDENCE/NON-COMPLIANCE LETTER" from the US FDA. US FDA has directed the Company to take certain corrective actions at the Mohali facility before releasing further final product batches into the US. These actions include, among others, retaining an independent CGMP expert to conduct batch certifications of drugs manufactured at the Mohali facility.

The Company is taking required corrective steps, but there will be a temporary pause in release of batches from Mohali until US FDA mandated measures are implemented. US shipments from Mohali will resume once these measures are in place.

This is for your information and dissemination.

Thanking you,

Yours faithfully,
For Sun Pharmaceutical Industries Limited

Anoop Deshpande
Company Secretary & Compliance Officer